ATE480776T1 - Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie - Google Patents

Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie

Info

Publication number
ATE480776T1
ATE480776T1 AT05766030T AT05766030T ATE480776T1 AT E480776 T1 ATE480776 T1 AT E480776T1 AT 05766030 T AT05766030 T AT 05766030T AT 05766030 T AT05766030 T AT 05766030T AT E480776 T1 ATE480776 T1 AT E480776T1
Authority
AT
Austria
Prior art keywords
immunotherapy
tumor
associated antigen
cancer diagnostics
cancer
Prior art date
Application number
AT05766030T
Other languages
German (de)
English (en)
Inventor
Chih-Sheng Chiang
John Simard
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35478743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE480776(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mannkind Corp filed Critical Mannkind Corp
Application granted granted Critical
Publication of ATE480776T1 publication Critical patent/ATE480776T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05766030T 2004-06-17 2005-06-17 Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie ATE480776T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58096904P 2004-06-17 2004-06-17
PCT/US2005/021836 WO2006002114A2 (en) 2004-06-17 2005-06-17 Tumor-associated antigen profiles in cancer diagnostics and immunotherapy

Publications (1)

Publication Number Publication Date
ATE480776T1 true ATE480776T1 (de) 2010-09-15

Family

ID=35478743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05766030T ATE480776T1 (de) 2004-06-17 2005-06-17 Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie

Country Status (10)

Country Link
EP (1) EP1782070B1 (https=)
JP (1) JP2008503498A (https=)
AT (1) ATE480776T1 (https=)
AU (1) AU2005258014B2 (https=)
CA (1) CA2571070A1 (https=)
DE (1) DE602005023488D1 (https=)
DK (1) DK1782070T3 (https=)
ES (1) ES2351995T3 (https=)
MX (1) MXPA06014771A (https=)
WO (1) WO2006002114A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP2032719A2 (en) * 2006-06-02 2009-03-11 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
GB0720118D0 (en) * 2007-10-15 2007-11-28 Achour Adnane Modified mhc class 1 binding peptides
WO2009068621A1 (en) * 2007-11-30 2009-06-04 Glaxosmithkline Biologicals S.A. Method for classifying cancer patients as responder or non-responder to immunotherapy
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
AU2009215503B2 (en) * 2008-02-20 2014-05-08 Arizona Cancer Therapeutics, Llc Use of therapeutic peptides for the treatment and prevention of cancer
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
AU2010229924B2 (en) 2009-03-24 2016-07-21 Plus Therapeutics Inc. Devices and methods of cell capture and analysis
JP2013544237A (ja) 2010-10-12 2013-12-12 アリゾナ バイオメディカル リサーチ コミッション Ｅｇｆｒベースのペプチド
US10066004B2 (en) 2010-10-12 2018-09-04 Arizona Cancer Therapeutics, Llc EGFR-based inhibitor peptides for combinatorial inactivation of ERBB1, ERBB2, and ERBB3
PE20141114A1 (es) 2010-12-20 2014-09-15 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
US20150044224A1 (en) * 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
WO2014074785A1 (en) * 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
WO2017176946A1 (en) * 2016-04-05 2017-10-12 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for targeted therapy based on single-cell stimulus perturbation response
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
US20220370586A1 (en) * 2019-08-08 2022-11-24 Cedars-Sinai Medical Center Method of generating activated t cells for cancer therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
US6794501B2 (en) 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
DE10225139A1 (de) * 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden

Also Published As

Publication number Publication date
AU2005258014B2 (en) 2012-07-12
EP1782070A2 (en) 2007-05-09
WO2006002114A2 (en) 2006-01-05
MXPA06014771A (es) 2007-03-21
WO2006002114A3 (en) 2006-10-05
ES2351995T3 (es) 2011-02-14
JP2008503498A (ja) 2008-02-07
DK1782070T3 (da) 2011-01-03
AU2005258014A1 (en) 2006-01-05
DE602005023488D1 (de) 2010-10-21
EP1782070B1 (en) 2010-09-08
CA2571070A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
ATE480776T1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
MX2007015946A (es) Combinaciones de antigenos asociados a tumor en diagnosticos para varios tipos de cancer.
TNSN05300A1 (en) Treatment with anti-vegf antibodies
NO20071791L (no) Preparater og fremgangsmater for diagnostiseringen og behandlingen av tumor
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
NO20084546L (no) Diagnostikk og behandlinger for tumorer
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
HUE037307T2 (hu) Tumor-asszociált antigének felismerése diagnózishoz és terápiához
DK1472541T3 (da) Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
WO2008066691A3 (en) Tes7 and antibodies that bind thereto
DK1587837T3 (da) Epitopsekvenser til diagnose og behandling af prostatacancer
CY2022028I1 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
EP1572087A4 (en) ANTIBODY TO CANCERANT TMEFF2 AND ITS APPLICATIONS
WO2006084075A3 (en) Adam-9 modulators
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
WO2005028498A3 (en) Kid3 and kid3 antibodies that bind thereto
PH12022552267A1 (en) Tie2-binding agents and methods of use
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
WO2010054377A3 (en) Fully human antibodies against n-cadherin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties